• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Occult Hepatocellular Carcinoma Associated With Transjugular Intrahepatic Portosystemic Shunts in Liver Transplant Recipients.经颈静脉肝内门体分流术相关隐匿性肝细胞癌肝移植受者。
Liver Transpl. 2021 Sep;27(9):1248-1261. doi: 10.1002/lt.26073. Epub 2021 Jul 21.
2
Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.经颈静脉肝内门体分流术联合其他干预措施治疗门静脉高压性肝细胞癌
World J Gastroenterol. 2015 Nov 21;21(43):12439-47. doi: 10.3748/wjg.v21.i43.12439.
3
Pretransplant Portal Vein Recanalization-Transjugular Intrahepatic Portosystemic Shunt in Patients With Complete Obliterative Portal Vein Thrombosis.完全闭塞性门静脉血栓形成患者移植前门静脉再通——经颈静脉肝内门体分流术
Transplantation. 2015 Nov;99(11):2347-55. doi: 10.1097/TP.0000000000000729.
4
Investigating the risk factors of hepatocellular carcinoma and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal hypertension.经颈静脉肝内门体分流术治疗门静脉高压后门静脉高压症患者肝细胞癌的危险因素及生存分析。
J Cancer Res Ther. 2018;14(4):826-832. doi: 10.4103/jcrt.JCRT_930_17.
5
Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.经颈静脉肝内门体分流术治疗合并门静脉癌栓的肝细胞癌门静脉高压症
Cardiovasc Intervent Radiol. 2017 Sep;40(9):1372-1382. doi: 10.1007/s00270-017-1655-8. Epub 2017 May 9.
6
Percutaneous transhepatic balloon-assisted transjugular intrahepatic portosystemic shunt for chronic, totally occluded, portal vein thrombosis with symptomatic portal hypertension: procedure technique, safety, and clinical applications.经皮经肝球囊辅助经颈静脉肝内门体分流术治疗慢性、完全闭塞性门静脉血栓形成伴症状性门静脉高压:操作技术、安全性和临床应用。
Eur Radiol. 2015 Dec;25(12):3431-7. doi: 10.1007/s00330-015-3777-1. Epub 2015 Apr 23.
7
Transjugular intrahepatic portosystemic shunt versus endoscopic therapy for prevention of variceal rebleeding in patients with hepatocellular carcinoma meeting the Milan criteria.经颈静脉肝内门体分流术与内镜治疗对符合米兰标准的肝细胞癌患者预防静脉曲张再出血的比较
Eur J Gastroenterol Hepatol. 2021 Mar 1;33(3):436-442. doi: 10.1097/MEG.0000000000001750.
8
TIPS for patients with early HCC: A bridge to liver transplantation.早期 HCC 患者的 TIPS:肝移植的桥梁。
Clin Res Hepatol Gastroenterol. 2022 Oct;46(8):101790. doi: 10.1016/j.clinre.2021.101790. Epub 2021 Aug 14.
9
The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer.经颈静脉肝内门体分流术对肝细胞癌诊断的影响。
PLoS One. 2018 Dec 28;13(12):e0208233. doi: 10.1371/journal.pone.0208233. eCollection 2018.
10
Transjugular Intrahepatic Portosystemic Shunt Is Associated With Better Waitlist Management of Liver Transplant Candidates With Hepatocellular Carcinoma.经颈静脉肝内门体分流术与肝细胞癌肝移植候选者更好的等待名单管理相关。
Transpl Int. 2024 Jun 26;37:12781. doi: 10.3389/ti.2024.12781. eCollection 2024.

引用本文的文献

1
Accuracy of cross-sectional imaging in predicting tumor viability using the LI-RADS treatment response algorithm after image-guided percutaneous ablation with radiologic-pathologic explant correlation.经皮图像引导下消融术后,利用LI-RADS治疗反应算法并结合放射病理学标本对照,横断面成像预测肿瘤活性的准确性。
Cancer Imaging. 2025 May 24;25(1):65. doi: 10.1186/s40644-025-00884-y.
2
Efficacy and safety of TACE combined with TKIs and PD-1 inhibitors in HCC patients with prior TIPS.经颈静脉肝内门体分流术(TIPS)治疗后肝细胞癌(HCC)患者中,肝动脉化疗栓塞术(TACE)联合酪氨酸激酶抑制剂(TKIs)及程序性死亡受体1(PD-1)抑制剂的疗效与安全性
Front Oncol. 2025 Apr 24;15:1570029. doi: 10.3389/fonc.2025.1570029. eCollection 2025.
3
Transjugular Intrahepatic Portosystemic Shunt Is Associated With Better Waitlist Management of Liver Transplant Candidates With Hepatocellular Carcinoma.经颈静脉肝内门体分流术与肝细胞癌肝移植候选者更好的等待名单管理相关。
Transpl Int. 2024 Jun 26;37:12781. doi: 10.3389/ti.2024.12781. eCollection 2024.
4
Risks and benefits of TIPS in HCC and other liver malignancies: a literature review.经颈静脉肝内门体分流术(TIPS)在 HCC 及其他肝脏恶性肿瘤中的风险和获益:文献综述。
BMC Gastroenterol. 2023 Nov 20;23(1):403. doi: 10.1186/s12876-023-03047-0.
5
Liver transplantation and hepatocellular carcinoma: is TIPS deleterious? A multicentric retrospective study of the ARCHET research group with propensity score matching.肝移植与肝细胞癌:TIPS 是否有害?ARCHET 研究组的一项多中心回顾性研究,采用倾向评分匹配。
Langenbecks Arch Surg. 2023 Apr 13;408(1):149. doi: 10.1007/s00423-023-02875-8.

本文引用的文献

1
The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer.经颈静脉肝内门体分流术对肝细胞癌诊断的影响。
PLoS One. 2018 Dec 28;13(12):e0208233. doi: 10.1371/journal.pone.0208233. eCollection 2018.
2
Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis.肝细胞癌的无创性影像学诊断与预后评估。
World J Gastroenterol. 2018 Jun 14;24(22):2348-2362. doi: 10.3748/wjg.v24.i22.2348.
3
Is de novo hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt increased?经颈静脉肝内门体分流术后新发肝细胞癌会增加吗?
United European Gastroenterol J. 2018 Apr;6(3):413-421. doi: 10.1177/2050640617732886. Epub 2017 Sep 20.
4
AASLD guidelines for the treatment of hepatocellular carcinoma.美国肝病研究学会肝细胞癌治疗指南。
Hepatology. 2018 Jan;67(1):358-380. doi: 10.1002/hep.29086.
5
Incidence of Occult Intrahepatic Metastasis in Hepatocellular Carcinoma Treated With Transplantation Corresponds to Early Recurrence Rates After Partial Hepatectomy.移植治疗肝细胞癌隐匿性肝内转移的发生率与部分肝切除术后早期复发率相对应。
Ann Surg. 2018 May;267(5):922-928. doi: 10.1097/SLA.0000000000002135.
6
Impact of transjugular intrahepatic portosystemic shunt implantation on liver perfusion measured by volume perfusion CT.经颈静脉肝内门体分流术植入对容积灌注CT测量的肝脏灌注的影响
Acta Radiol. 2017 Oct;58(10):1167-1173. doi: 10.1177/0284185116685922. Epub 2017 Jan 13.
7
Toward a Comprehensive New Classification of Portal Vein Thrombosis in Patients With Cirrhosis.肝硬化患者门静脉血栓形成的全面新分类研究
Gastroenterology. 2016 Oct;151(4):574-577.e3. doi: 10.1053/j.gastro.2016.08.033. Epub 2016 Aug 27.
8
Current Status of Liver Allocation in the United States.美国肝脏分配的现状
Gastroenterol Hepatol (N Y). 2016 Mar;12(3):166-70.
9
Washout of hepatocellular carcinoma on portal venous phase of multidetector computed tomography in a pre-transplant population.多排螺旋计算机断层扫描门静脉期肝移植前人群肝细胞癌的洗脱情况
J Med Imaging Radiat Oncol. 2015 Dec;59(6):673-80. doi: 10.1111/1754-9485.12347. Epub 2015 Aug 4.
10
The Presence of Portal Vein Thrombosis Alters the Classic Enhancement Associated with Diagnosis of Hepatocellular Carcinoma.门静脉血栓形成的存在改变了与肝细胞癌诊断相关的典型强化表现。
Dig Dis Sci. 2015 Jul;60(7):2196-200. doi: 10.1007/s10620-015-3587-y. Epub 2015 Mar 17.

经颈静脉肝内门体分流术相关隐匿性肝细胞癌肝移植受者。

Occult Hepatocellular Carcinoma Associated With Transjugular Intrahepatic Portosystemic Shunts in Liver Transplant Recipients.

机构信息

Division of Transplant, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA.

Department of Biostatistics, Hospital of the University of Pennsylvania, Philadelphia, PA.

出版信息

Liver Transpl. 2021 Sep;27(9):1248-1261. doi: 10.1002/lt.26073. Epub 2021 Jul 21.

DOI:10.1002/lt.26073
PMID:33853207
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8429178/
Abstract

Transplant eligibility for hepatocellular carcinoma (HCC) is determined by the imaging identification of tumor burden within the Milan criteria. Transjugular intrahepatic portosystemic shunt(s) (TIPS) reduce portal hypertension but may impact HCC visualization. It was hypothesized that the presence of pretransplant TIPS would correlate with occult HCC and reduced survival. A single-center, retrospective, case control study was performed among liver transplant recipients with HCC (2000-2017). The primary endpoint was occult disease on explant pathology. Backward stepwise logistic regression was performed. The secondary endpoints disease-free survival (DFS) and overall survival (OS) were evaluated with Kaplan-Meier curves and Cox regression analysis. Of 640 patients, 40 had TIPS and more frequently exhibited occult disease (80.0% versus 43.1%; P < 0.001; odds ratio [OR], 4.16; P < 0.001). Portal vein thrombosis (PVT) similarly correlated with occult disease (OR, 1.97; P = 0.02). Explant tumor burden was equivalent between TIPS subgroups; accordingly, TIPS status was not independently associated with reduced DFS or OS. However, exceeding the Milan criteria was associated with reduced DFS (hazard ratio, 3.21; P = 0.001), and TIPS status in patients with a single suspected lesion (n = 316) independently correlated with explant tumor burdens beyond these criteria (OR, 13.47; P = 0.001). TIPS on pretransplant imaging are associated with occult HCC on explant pathology. Comparable occult disease findings in patients with PVT suggest that the mechanism may involve altered hepatic perfusion, obscuring imaging diagnosis. TIPS are not independently associated with reduced DFS or OS but are associated with exceeding the Milan criteria for patients with a single suspected lesion. The presence of TIPS may necessitate a higher index of suspicion for occult HCC.

摘要

肝移植候选者的肝癌(HCC)标准是通过米兰标准确定的肿瘤负荷影像鉴定。经颈静脉肝内门体分流术(TIPS)可以降低门静脉高压,但可能会影响 HCC 的可视化。研究假设移植前 TIPS 的存在与隐匿性 HCC 和生存率降低相关。对 2000 年至 2017 年接受 HCC 肝移植的患者进行了单中心、回顾性病例对照研究。主要终点是移植肝标本的隐匿性疾病。采用后退逐步逻辑回归。采用 Kaplan-Meier 曲线和 Cox 回归分析评估无病生存(DFS)和总生存(OS)的次要终点。在 640 例患者中,40 例患者存在 TIPS,隐匿性疾病更为常见(80.0%比 43.1%;P < 0.001;比值比[OR],4.16;P < 0.001)。门静脉血栓形成(PVT)同样与隐匿性疾病相关(OR,1.97;P = 0.02)。TIPS 亚组的移植肝肿瘤负荷相当;因此,TIPS 状态与 DFS 或 OS 降低无关。然而,超过米兰标准与 DFS 降低相关(风险比,3.21;P = 0.001),并且在 316 例仅有单个可疑病变的患者中,TIPS 状态与超出这些标准的移植肝肿瘤负荷独立相关(OR,13.47;P = 0.001)。移植前影像学上的 TIPS 与移植肝标本的隐匿性 HCC 相关。在有 PVT 的患者中发现类似的隐匿性疾病提示,其机制可能涉及肝灌注改变,使影像学诊断变得模糊。TIPS 与 DFS 或 OS 降低无关,但与仅有单个可疑病变的患者超过米兰标准相关。TIPS 的存在可能需要对隐匿性 HCC 保持更高的警惕性。